ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.912,78
2,82%
S&P 500
6.071,17
0,53%
US Dollar vs BRL
5,8756
-0,01%
Bitcoin
104.670,28
-0,06%
Brent Oil
76,265
0,28%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. PainReform Ltd (PRFX)

  7. PainReform Ltd (PRFX) Notícias

PRFX

PainReform (PRFX)

PainReform Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRFX
DataHoraFonteTítuloCódigoCompanhia
02/01/202518:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRFXPainReform Ltd
02/01/202518:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
27/12/202410:30GlobeNewswire Inc.PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110NASDAQ:PRFXPainReform Ltd
13/12/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
12/12/202419:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PRFXPainReform Ltd
06/12/202418:30Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRFXPainReform Ltd
20/11/202410:30GlobeNewswire Inc.PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNASDAQ:PRFXPainReform Ltd
07/11/202419:00GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNASDAQ:PRFXPainReform Ltd
11/09/202409:30GlobeNewswire Inc.PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
10/09/202410:46GlobeNewswire Inc.PainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsNASDAQ:PRFXPainReform Ltd
28/08/202417:30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:PRFXPainReform Ltd
27/08/202418:07Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRFXPainReform Ltd
21/08/202409:30GlobeNewswire Inc.PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresNASDAQ:PRFXPainReform Ltd
20/08/202409:30GlobeNewswire Inc.PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyNASDAQ:PRFXPainReform Ltd
15/08/202409:00GlobeNewswire Inc.PainReform Provides Business Update for the Second Quarter of 2024NASDAQ:PRFXPainReform Ltd
12/08/202410:00GlobeNewswire Inc.PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsNASDAQ:PRFXPainReform Ltd
07/08/202411:00GlobeNewswire Inc.PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesNASDAQ:PRFXPainReform Ltd
05/08/202410:00GlobeNewswire Inc.PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
01/08/202409:30GlobeNewswire Inc.PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureNASDAQ:PRFXPainReform Ltd
24/07/202409:30GlobeNewswire Inc.PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingNASDAQ:PRFXPainReform Ltd
26/06/202409:00GlobeNewswire Inc.PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110NASDAQ:PRFXPainReform Ltd
31/05/202417:15GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:PRFXPainReform Ltd
15/05/202417:05GlobeNewswire Inc.PainReform Provides Business Update for the First Quarter of 2024NASDAQ:PRFXPainReform Ltd
08/05/202409:30GlobeNewswire Inc.PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comNASDAQ:PRFXPainReform Ltd
18/04/202415:19GlobeNewswire Inc.PainReform Announces Closing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
16/04/202409:00GlobeNewswire Inc.PainReform Announces Pricing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
09/04/202410:00GlobeNewswire Inc.PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsNASDAQ:PRFXPainReform Ltd
02/04/202409:30GlobeNewswire Inc.PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyNASDAQ:PRFXPainReform Ltd
01/03/202418:34Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:PRFXPainReform Ltd
01/03/202410:00GlobeNewswire Inc.PainReform Provides Year-End Business UpdateNASDAQ:PRFXPainReform Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRFX

Seu Histórico Recente

USOTC
PJET
Priority Aviation (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios